ELISA Kit for Glypican 3 (GPC3)

0.156-10ng/mL

The minimum detectable dose of this kit is typically less than 0.057ng/mL

3h

This assay has high sensitivity and excellent specificity for detection of Glypican 3 (GPC3).
No significant cross-reactivity or interference between Glypican 3 (GPC3) and analogues was observed.

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Glypican 3 (GPC3). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Glypican 3 (GPC3). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Glypican 3 (GPC3), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Glypican 3 (GPC3) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Diagnostic Role of Serum Glypican-3 as a Tumor Marker for Hepatocellular Carcinoma ; Cytotoxic effects of antiglypican-3 against HepG2 cell line; Can Glypican3 be Diagnostic for Early Hepatocellular Carcinoma among Egyptian Patients?; Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: A systematic review and meta-analysis; Diagnostic Role of Serum Glypican-3 as Hepatocellular Carcinoma; Role of serum glypican-3 in the diagnosis and differentiation of small hepatocellular carcinoma from hepatitis-C virus cirrhosis; Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.; Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma; Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern; Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis; Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment; Cytotoxic and partial hepatoprotective activity of sodium ascorbate against hepatocellular carcinoma through inhibition of sulfatase-2 and; Development and Validation of a Two-Site Immunoradiometric assay for Glypican-3 in plasma: Implication in Diagnosis of Hepatocellular Carcinoma; Serum Glypican-3, Vascular Endothelial Growth Factor, and Interleukin-6 Levels in Hepatocellular Carcinoma; Elevated plasma glypicans are associated with organ failure in patients with infection;